Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Sanofi-Aventis New Zealand Limited,Eliglustat,type 1 or type 3 Gaucher disease,Eliglustat (Cerdelga),Only if cost neutral or cost saving,Community,
